TNFSF11 and osteoporosis: Several antibodies targeting RANKL are FDA-approved, or are in late stage clinical trials for the treatment of osteoporosis and cancer-induced bone loss, and there are keen interests in targeting Siglec-15 for the same therapeutic applications54–56.